Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
25 January 2018Website:
http://www.vynetherapeutics.comNext earnings report:
14 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 18:28:20 GMTDividend
Analysts recommendations
Institutional Ownership
VYNE Latest News
Boston event to focus on Immunology & Inflammation (I&I) and Metabolic Diseases Boston event to focus on Immunology & Inflammation (I&I) and Metabolic Diseases
VYN202 has been designed to achieve class-leading potency and BD2-selectivity Trial will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of VYN202 in healthy volunteers; top-line data expected in 2H'24 BRIDGEWATER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that the first healthy volunteers have been dosed in the Phase 1a trial of VYN202.
After losing some value lately, a hammer chart pattern has been formed for VYNE Therapeutics Inc. (VYNE), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
VYNE Therapeutics Inc. (VYNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
VYNE gains on positive preclinical data evaluating VYN201 for treating idiopathic pulmonary fibrosis.
What type of business is VYNE Therapeutics?
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
What sector is VYNE Therapeutics in?
VYNE Therapeutics is in the Healthcare sector
What industry is VYNE Therapeutics in?
VYNE Therapeutics is in the Biotechnology industry
What country is VYNE Therapeutics from?
VYNE Therapeutics is headquartered in United States
When did VYNE Therapeutics go public?
VYNE Therapeutics initial public offering (IPO) was on 25 January 2018
What is VYNE Therapeutics website?
https://www.vynetherapeutics.com
Is VYNE Therapeutics in the S&P 500?
No, VYNE Therapeutics is not included in the S&P 500 index
Is VYNE Therapeutics in the NASDAQ 100?
No, VYNE Therapeutics is not included in the NASDAQ 100 index
Is VYNE Therapeutics in the Dow Jones?
No, VYNE Therapeutics is not included in the Dow Jones index
When does VYNE Therapeutics report earnings?
The next expected earnings date for VYNE Therapeutics is 14 August 2024